Holen Sie sich die Stockscreener-App
3.32
7.64%
0.23
Schlusskurs vom Vortag:
$3.09
Offen:
$3.19
24-Stunden-Volumen:
3.36M
Relative Volume:
1.15
Marktkapitalisierung:
$887.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-252.18M
KGV:
-3.1321
EPS:
-1.06
Netto-Cashflow:
$-185.29M
1W Leistung:
+5.59%
1M Leistung:
-13.61%
6M Leistung:
+3.30%
1J Leistung:
+25.28%
1-Tages-Spanne:
$3.18
$3.38
1-Wochen-Bereich:
$3.00
$3.48
52-Wochen-Spanne:
$1.26
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.325 | 824.62M | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.20 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.51 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.45 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | Wedbush | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-03-18 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-11-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
Sana Biotechnology reports 14-month data on diabetes cell therapy - Investing.com
Transplanted insulin cells work 14 months without immune drugs in T1D patient - Stock Titan
Earnings Report: Will Sana Biotechnology Inc benefit from sector rotation2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
SANA: Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon - TradingView
VIX Spike: Can Sana Biotechnology Inc be the next market leader2026 Chart Watch & Comprehensive Market Scan Reports - baoquankhu1.vn
Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors - Sahm
Aug Drivers: Is Sana Biotechnology Inc attractive at current valuation2025 Market Trends & Short-Term High Return Ideas - baoquankhu1.vn
TD Cowen reiterates Buy rating on Sana Biotechnology stock By Investing.com - Investing.com Canada
TD Cowen reiterates Buy rating on Sana Biotechnology stock - Investing.com UK
Q1 EPS Estimate for Sana Biotechnology Lowered by Analyst - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade - MarketBeat
What is HC Wainwright's Forecast for SANA FY2030 Earnings? - MarketBeat
Seattle InnoCajal raises $96M I Layoffs at Sana - The Business Journals
Sana Biotechnology (NASDAQ:SANA) Cut to Hold at Zacks Research - MarketBeat
Citizens reiterates Sana Biotechnology stock rating on pipeline progress By Investing.com - Investing.com Nigeria
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks - TipRanks
Sana Biotechnology Diabetes Data And CAR T Plans Shape Pipeline Outlook - simplywall.st
Sana Biotechnology (SANA) Q4 2025 Financial Results: Net Loss and Analyst OutlookNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $7.00 at HC Wainwright - MarketBeat
Sana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down - Nasdaq
Sana Biotechnology files for mixed shelf size not disclosedSEC filing - marketscreener.com
Sana Biotechnology Files For Mixed Shelf Size Not DisclosedSEC Filing - TradingView
Sana Biotechnology (NASDAQ: SANA) files ATM to raise up to $150M with TD Cowen - Stock Titan
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - Bitget
Sana: Overview of Fourth Quarter Financial Results - Bitget
Sana Biotechnology Updates ATM Program to Support Development - TipRanks
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q4 Adjusted Loss $0.16 per Share, vs. FactSet Est of $-0.14 - marketscreener.com
Going concern risk and focused pipeline at Sana Biotechnology (NASDAQ: SANA) - Stock Titan
Sana Biotechnology (NASDAQ: SANA) sets $150.0 million ATM program - Stock Titan
SANA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sana Biotechnology, Inc. (SANA): A Bull Case Theory - Yahoo Finance
Sana Biotechnology (SANA) Stock Analysis: Exploring a Potential 104% Upside with Innovative Cell Therapies - DirectorsTalk Interviews
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO - Yahoo Finance
Assessing Sana Biotechnology (SANA) Valuation After The Appointment Of A New CFO - Yahoo Finance
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - simplywall.st
Sana Biotechnology to Present at March 2026 Investor Conferences - GlobeNewswire
Is Sana Biotechnology Inc a stock for growth or value investorsTreasury Yields & Daily Oversold Bounce Ideas - baoquankhu1.vn
Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - TradingView
Sana Biotechnology (SANA) CFO awarded new RSUs and 900,000 options - Stock Titan
Sana Biotechnology Names Brian Piper as New CFO - The Globe and Mail
All You Need to Know About Sana (SANA) Rating Upgrade to Buy - MSN
Sana Biotechnology stock falls after naming new CFO By Investing.com - Investing.com South Africa
Sana Biotechnology, Inc. Appoints Brian Piper as Chief Financial Officer - marketscreener.com
Sana Biotechnology, Inc. Announces Executive Changes - marketscreener.com
Sana Biotechnology stock falls after naming new CFO - Investing.com
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer - Bitget
Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects - MSN
What’s the outlook for Sana Biotechnology Inc.’s sectorGDP Growth & Proven Capital Preservation Tips - mfd.ru
Assessing Sana Biotechnology (SANA) Valuation As Analyst Downgrade And FDA Scrutiny Weigh On Sentiment - Sahm
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sana Biotechnology Inc-Aktie (SANA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):